The Zacks Analyst Blog Highlights:Colgate-Palmolive, Procter & Gamble, Clorox, Inter Perfums and Bank of New York Mellon

The Zacks Analyst Blog Highlights:Colgate-Palmolive, Procter & Gamble, Clorox,
                  Inter Perfums and Bank of New York Mellon

PR Newswire

CHICAGO, Jan. 31, 2013

CHICAGO, Jan. 31, 2013 /PRNewswire/ announces the list of stocks
featured in the Analyst Blog. Every day the Zacks Equity Research analysts
discuss the latest news and events impacting stocks and the financial markets.
Stocks recently featured in the blog include Colgate-Palmolive Company
(NYSE:CL), Procter & Gamble Company (NYSE:PG), The Clorox Company (NYSE:CLX),
Inter Perfums Inc. (Nasdaq:IPAR) and The Bank of New York Mellon Corporation


Get the most recent insight from Zacks Equity Research with the free Profit
from the Pros newsletter:

Here are highlights from Wednesday's Analyst Blog:

Will Colgate-Palmolive Beat in 4Q?

World's leading consumer goods dealer,Colgate-Palmolive Company (NYSE:CL) is
likely to beat the expectations when it reports its fiscal 2012 fourth-quarter
results on Jan 31.

Why a Likely Positive Surprise?

Our proven model shows that Colgate-Palmolive may beat the earnings because it
has the right combination of two key components – Positive Earnings ESP (Read:
Zacks Earnings ESP: A Better Method) and a Zacks Rank #2.

ZacksESP: Colgate-Palmolive currently has an Earnings ESP of +1.43%. This is
because the Most Accurate Estimate stands at $1.42, while the Zacks Consensus
Estimate is pegged at $1.40.

Zacks#2 Rank (Buy): Note that stocks with Zacks Rank #1, #2 and #3 have
significantly higher chances of beating the earnings. The sell rated stocks
(#4 and #5) should never be considered going into an earnings announcement.

The combination of Colgate-Palmolive's Zacks Rank #2 (Buy) and Earnings ESP of
+1.43% make us confident regarding a positive earnings beat by the company on
Jan 31.

What is Driving the Better-than-Expected Earnings?

We believe that the company's strategic acquisition and divestment activities,
along with sustained focus on product innovation, provide it a platform to
take advantage of growth opportunities, and thereby augment profitability.

The company has met as well as surpassed the Zacks Consensus Estimate in
trailing four quarters with an average surprise of approximately 0.8%.

Other Stocks to Consider

Colgate-Palmolive is not the only firm looking up this earnings season. The
following companies – Colgate's industry peers – are also likely to beat the
earnings in the to-be-reported quarter:

Procter & Gamble Company (NYSE:PG) with Earnings ESP of +2.08% and a Zacks
Rank #2 (Buy).

The Clorox Company (NYSE:CLX) with Earnings ESP of +1.24% and a Zacks Rank #3

Inter Perfums Inc. (Nasdaq:IPAR

) has Earnings ESP of +13.33% and carries a Zacks Rank #3 (Hold).

BNY Mellon's Dismissal Plea Refused

The Supreme Court of the State of New York has rejected a dismissal plea of
The Bank of New York Mellon Corporation (NYSE:BK). A lawsuit was filed by The
Salvation Army accusing BNY Mellon of mismanaging funds.

The New York Judge has sustained three out four claims in the Salvation Army's
lawsuit against BNY Mellon's gross negligence, breach of fiduciary duty and
breach of contract. However, the claim for negligent misrepresentation was
dismissed. The Salvation Army is seeking $22 million in compensation.

In Apr 2011, the southern division of the Salvation Army had filed the lawsuit
alleging gross ignorance on part of BNY Mellon regarding the investment of the
charity's funds. The Salvation Army's instructions of investing in less risky
avenues were not followed by the bank. Rather, BNY Mellon went ahead and
invested funds in perilous mortgage-backed securities. Consequently, when the
markets collapsed, the Salvation Army suffered huge losses.

In its defense, BNY Mellon was quick to point that the investment strategy at
during that particular period was prudent enough and it had meticulously
executed the investment of the charity's funds. Further, the bank added that
it was willing to challenge the charges in the court.

Presently, BNY Mellon is not the only bank facing problems over investment in
mortgage-backed securities prior to 2008 financial crisis.

Want more from Zacks Equity Research? Subscribe to the free Profit from the
Pros newsletter:

About Zacks Equity Research

Zacks Equity Research provides the best of quantitative and qualitative
analysis to help investors know what stocks to buy and which to sell for the

Continuous coverage is provided for a universe of 1,150 publicly traded
stocks. Our analysts are organized by industry which gives them keen insights
to developments that affect company profits and stock performance.
Recommendations and target prices are six-month time horizons.

Zacks "Profit from the Pros" e-mail newsletter provides highlights of the
latest analysis from Zacks Equity Research. Subscribe to this free newsletter

About Zacks is a property of Zacks Investment Research, Inc., which was formed
in 1978 by Leon Zacks. As a PhD from MIT Len knew he could find patterns in
stock market data that would lead to superior investment results. Amongst his
many accomplishments was the formation of his proprietary stock picking
system; the Zacks Rank, which continues to outperform the market by nearly a 3
to 1 margin. The best way to unlock the profitable stock recommendations and
market insights of Zacks Investment Research is through our free daily email
newsletter; Profit from the Pros. In short, it's your steady flow of
Profitable ideas GUARANTEED to be worth your time! Register for your free
subscription to Profit from the Pros at

Visit for information about the performance
numbers displayed in this press release.

Follow us on Twitter:

Join us on Facebook:

Disclaimer: Past performance does not guarantee future results. Investors
should always research companies and securities before making any investments.
Nothing herein should be construed as an offer or solicitation to buy or sell
any security.

Media Contact

Zacks Investment Research

800-767-3771 ext. 9339

SOURCE Zacks Investment Research, Inc.

Press spacebar to pause and continue. Press esc to stop.